Pramipexol en el hipo intratable

Martínez-Ruiz, Mario; Riestra, Francisco de Asís Fernández; Rubio, Roberto

doi:10.1157/13068702

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…inducing hiccups (Miyaoka and Kamijima, 1999;Cheng et al, 2011). • Reports of dopaminergic agonists (amantadine, apomorphine, pergolide, pramipexole, piribedil, levodopa, ropinrole) used to treat hiccup (Welsh, 1904;Garrick, 1917;Askenasy et al, 1988;Martinez-Ruiz et al, 2004;Sharma et al, 2006;Lester et al, 2007;Gerschlager and Bloem, 2009;Coletti Moja, 2010). • Reports of failure of selective anti-dopaminergic agents (haloperidol) to control hiccups (Nishikawa et al, 2015).…”

Section: Evidence Against Dopaminergic Involvementmentioning

confidence: 99%

See 1 more Smart Citation

The Role of Serotonin in Singultus: A Review

Petroianu

Lorke

2020

Front. Neurosci.

View full text Add to dashboard Cite

The use of dopamine receptor blockers for chronic singultus treatment is basedat least partially-on circular thinking: chlorpromazine is FDA-approved for hiccups, chlorpromazine is a neuroleptic, neuroleptics are dopamine receptor blockers, and therefore hiccup is due to dopaminergic dysfunction. Chlorpromazine interacts with high affinity with a multitude of receptors and ion channels. This promiscuity is the basis for many of the therapeutic effects and adverse drug reactions of this drug. While an involvement of dopamine is certain, it is by no means clear that dopaminergic dysfunction is the hallmark of singultus. The common denominator of most remedies for transient hiccup is their ability to activate the vagus nerve. Both afferent and efferent vagal activity and the central integration of the Xth cranial nerve function are modulated, inter alia, via serotonergic mechanisms; beneficial (therapeutic) effects for hiccup are to be expected from serotonin (5-HT) receptor subtype ligands that enhance vagal activity. Taken together, it appears that the ability to increase vagus output is mainly associated with 5-HT 1A , 5-HT 3 , and 5-HT 7 agonists and with 5-HT 2C antagonists. The plausibility of the serotonergic singultus hypothesis is examined against available pharmacokinetic, pharmacodynamic, and clinical data for a number of drugs.

show abstract

Section: Evidence Against Dopaminergic Involvementmentioning

confidence: 99%

“…Reports of dopaminergic agonists ( amantadine, apomorphine, pergolide, pramipexole, piribedil, levodopa, ropinrole ) used to treat hiccup ( Welsh, 1904 ; Garrick, 1917 ; Askenasy et al, 1988 ; Martinez-Ruiz et al, 2004 ; Sharma et al, 2006 ; Lester et al, 2007 ; Gerschlager and Bloem, 2009 ; Coletti Moja, 2010 ).…”

Section: Introductionmentioning

confidence: 99%

The Role of Serotonin in Singultus: A Review

Petroianu

Lorke

2020

Front. Neurosci.

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4] Loss of substantia nigra dopaminergic neurons is a requirement for the pathological diagnosis of corticobasal degeneration (CBD). 5 Whether these neurons also degenerate in sCJD with acute corticobasal presentation is currently unknown.…”

Section: Sparing Of the Substantia Nigra In Sporadic Creutzfeldt-jakomentioning

confidence: 99%

Hiccup secondary to dopamine agonists in Parkinson's Disease

Lester¹,

Raina

Uribe-Roca

et al. 2007

Movement Disorders

View full text Add to dashboard Cite

Hiccup is produced by a sudden contraction of the inspiratory muscles followed by an abrupt closure of the glottis, which produces the typical sound that characterizes this disorder. The causes of hiccup are diverse, 1 including several drugs. 2 Here, we report two cases of patients with Parkinson's Disease (PD) who developed hiccup after using different dopamine agonists (DAs). CLINICAL CASES Case 1This 76-year-old man with a history of arterial hypertension, acute myocardial infarction (AMI) in 1988, and hypercholesterolemia developed progressive resting tremor and bradykinesia, initially involving the left side of his body and later becoming bilateral.He was given a diagnosis of PD 7 years ago and received levodopa/benserazide (500/120 mg/day) and piribedil (150 mg/ day) divided in three doses for the last 8 months. However, because of economic reasons and issues related to his medical insurance, the patient asked if he could change piribedil for another drug. To this end, he started pramipexol (3 mg/day). Two hours after taking the first pramipexol dose, however, he developed hiccups, which persisted for 3 days and stopped after discontinuing pramipexol. He was then switched back to piribedil at a higher dose than his original prescription (200 mg/day) but once again hiccups developed. They stopped after he decreased the dose to 150 mg/day.

show abstract

Pramipexol en el hipo intratable

Cited by 2 publications

References 0 publications

The Role of Serotonin in Singultus: A Review

The Role of Serotonin in Singultus: A Review

Hiccup secondary to dopamine agonists in Parkinson's Disease

Contact Info

Product

Resources

About